VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: Prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1445-1451

  Fushida, Sachio ^a   Oyama, Katsunobu ^a   Kinoshita, Jun ^a   Yagi, Yasumichi ^a   Okamoto, Kouichi ^a   Tajima, Hidehiro ^a   Ninomiya, Itasu ^a   Fujimura, Takashi ^a   Ohta, Tetsuo ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bevacizumab; Gastric cancer; Malignant ascites; Peritoneal metastasis; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; DOCETAXEL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL; VASCULOTROPIN;

ABDOMINAL DISTENSION; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MALE; MALIGNANT ASCITES; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARACENTESIS; PERITONEUM METASTASIS; PROTEIN BLOOD LEVEL; STOMACH CANCER; TOTAL STOMACH RESECTION;

EID: 84885991077     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S51916     Document Type: Article

References (42)

1. Allum WH, Powell DJ, McConkey CC, Fielding JW. Gastric cancer: a 25-year review. Br J Surg. 1989;76(6):535-540.
2. Maruyama K, Kaminishi M, Hayashi K, et al. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Japanese Gastric Cancer Association Registration Committee. Gastric Cancer. 2006;9(2):51-66.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-4997.
4. Koizumi W, Narahara H, Hata T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215-221.
5. Sato Y, Takayama T, Sagawa T, et al. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol. 2010;66(4): 721-728.
6. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancies. A prospective study of prognostic factors. Cancer. 1989;63(2):364-367.
7. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358-363.
8. Yonemura Y, Endou Y, Yamaguchi T, et al. Mechanisms of the formation of the peritoneal dissemination in gastric cancer. Int J Oncol. 1996;8(4):795-802.
9. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84(5):1470-1478.
10. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306-1309.
11. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer. Inhibition of ascites formation by immunoneutralization. Am J Pathol. 1998;153(4):1249-1256.
12. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 2003;9(15):5721-5728.
13. Sherer DM, Eliakim R, Abulafia O. The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. Gynecol Obstet Invest. 2000;50(4): 217-224.
14. Aoyagi K, Kouhuji K, Yano S, et al. VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer. 2005;8(3):155-163.
15. Li L, Wang L, Zhang W, et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 2004;24(3b):1973-1980.
16. Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med. 2004;98(7):632-636.
17. Alabi AA, Suppiah A, Madden LA, Monson JR, Greenman J. Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients. Dis Colon Rectum. 2009;52(5):993-999.
18. Vidal O, Metges JP, Elizalde I, et al. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg. 2009;96(12):1443-1451.
19. Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma. 1st English ed. Tokyo, Japan: Kanehara; 1995.
20. Kinoshita J, Fushida S, Makino I, et al. [The use of bevacizumab in refractory peritoneal dissemination of gastric cancer with malignant ascites-two case reports.] Gan To Kagaku Ryoho. 2011;38(12): 2360-2362. Japanese.
21. Kamiyama M, Ichikawa Y, Ishikawa T, et al. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene Ther. 2002;9(2):197-201.
22. Baba M, Konno H, Maruo Y, et al. Relationship of p53 and vascular endothelial growth factor expression of clinicopathological factors in human scirrhous gastric cancer. Eur Surg Res. 1998;30(2):130-137.
23. Imaizumi T, Aoyagi K, Miyagi M, Shirouzu K. Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model. Surg Today. 2010;40(9):851-857.
24. Sako A, Kitayama J, Yamaguchi H, et al. Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasis. J Surg Res. 2003;115(1):113-120.
25. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cell. J Biol Chem. 1994;269(9):6271-6274.
26. Hermey JH, Dimitriadis E, Kay E, Rdmond HP, Bouchier-Hayes D. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol. 1998;5(3):271-278.
27. Rudlowski C, Pickart AK, Fuhljahn C, et al. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer. 2006;16 Suppl 1:S183-S189.
28. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77(5):858-863.
29. Saito H, Tsujitani S, Kondo A, Ikeguchi M, Maeta M, Kaibara N. Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. Surgery. 1999;125(2):195-201.
30. Ichikura T, Tomimatsu S, Ohkura E, Mochizuki H. Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol. 2001;78(2): 132-137.
31. Karayiannakis AJ, Syrigos KN, Polychrondis A, et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg. 2002;236(1):37-42.
32. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S. Plasma concentration of VEGF and b-FGF in patients with gastric carcinoma. Cancer Lett. 2000;153(1-2):7-12.
33. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter Phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophaeal junction adenocarcinoma. J Clin Oncol. 2006;24(33):5201-5206.
34. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968-3976.
35. Della Porta M, Danova M, Rigolin GM, et al. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicopathological findings. Oncology. 2005;68(2-3):276-284.
36. Li B, Lalani AS, Harding TC, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res. 2006;12(22):6808-6816.
37. Bamias A, Koutsoukou V, Terpos E, et al. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFa in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol. 2008;108(2):421-427.
38. Zhang XS, Zhu XF, Gao JS, et al. Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165. Acta Pharmacol Sin. 2001;22(8):731-735.
39. Ninomiya S, Inomata M, Tajima M, et al. Effect of bevacizumab monoclonal antibody to vascular endothelial growth factor, on peritoneal matastasis of MKN-45P human gastric cancer in mice. J Surg Res. 2009;154(2):196-202.
40. Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 2006;102(3):425-428.
41. Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose S. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 2008;111(3): 530-532.
42. Yagi Y, Fushida S, Harada S, et al. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemother Pharmacol. 2010;66(4):745-753.